Gil M. Labrucherie Buys 10,500 Shares of Septerna, Inc. (NASDAQ:SEPN) Stock

Septerna, Inc. (NASDAQ:SEPN) CFO Gil M. Labrucherie acquired 10,500 shares of Septerna stock in a transaction on Wednesday, February 19th. The stock was purchased at an average cost of $5.51 per share, for a total transaction of $57,855.00. Following the purchase, the chief financial officer now owns 10,500 shares in the company, valued at approximately $57,855. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Septerna Stock Performance

NASDAQ SEPN opened at $5.80 on Friday. The firm’s 50 day moving average is $17.78. Septerna, Inc. has a fifty-two week low of $4.17 and a fifty-two week high of $28.99.

Hedge Funds Weigh In On Septerna

Several large investors have recently modified their holdings of SEPN. Tower Research Capital LLC TRC purchased a new position in Septerna during the 4th quarter valued at $25,000. New York State Common Retirement Fund purchased a new position in Septerna during the 4th quarter valued at $32,000. Legal & General Group Plc purchased a new position in Septerna during the 4th quarter valued at $42,000. Summit Investment Advisors Inc. purchased a new position in Septerna during the 4th quarter valued at $45,000. Finally, BNP Paribas Financial Markets purchased a new position in Septerna during the 4th quarter valued at $52,000.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Wells Fargo & Company downgraded Septerna from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $43.00 to $14.00 in a research note on Tuesday, February 18th. Cantor Fitzgerald reissued an “overweight” rating and set a $50.00 target price on shares of Septerna in a research report on Tuesday, February 11th. TD Cowen began coverage on Septerna in a research report on Tuesday, November 19th. They set a “buy” rating on the stock. Finally, JPMorgan Chase & Co. began coverage on Septerna in a research report on Tuesday, November 19th. They set an “overweight” rating and a $38.00 target price on the stock.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.